Studies of Ocular Complications of AIDS - Chairman's Office

艾滋病眼部并发症的研究 - 主席办公室

基本信息

  • 批准号:
    7891072
  • 负责人:
  • 金额:
    $ 43.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Studies of the Ocular Complications of AIDS Research Group is dedicated to understanding and improving the outcomes of the ocular complications of AIDS. The Longitudinal Study of the Ocular Complications of AIDS (LSOCA) is a prospective cohort study of these complications and their outcomes in the era of highly active antiretroviral therapy (HAART), and is currently in its ninth year of follow-up. Unlike most cohort studies of HIV-infected patients, which enroll from selected risk groups, LSOCA enrolls patients with AIDS from all risk groups. As of 31 December 2006 the LSOCA cohort has recruited 2024 patients, of whom 448 have cytomegalovirus retinitis and 18 have other ocular opportunistic infections (Ols). Although HAART has decreased the incidence of ocular Ols among patients with AIDS, new cases continue to occur, and there is an increasingly large number of patients with AIDS and ocular Ols who have experienced immune recovery. Although short-term outcomes have been described, no long-term data are available, and the durability of the response to HAART among these patients is unknown. Long-term data are critical for assessing resource needs and determining management guidelines. There also are abnormalities of the visual system among patients with AIDS without ocular Ols, manifested as decreased contrast sensitivity, often of sufficient magnitude to impair reading speed, and as visual field loss. Little is known about the pathogenesis of, the risk factors for, and the course of this neuroretinal disorder, particularly its long-term consequences. In addition, there appears to be an increased prevalence of cataract among patients with AIDS without ocular Ols, which may be aggravated by the metabolic side effects of HAART, such as diabetes and hyperlipidemia. Host genetic factors have a substantial effect on the course of HIV infection, but their effect on the incidence and course of ocular complications is unknown. The immunologic mechanisms underlying ocular complications also need to be elucidated better. The LSOCA cohort will address the ongoing need for long-term data in these areas. The specific aims of this proposal are to evaluate the following among patients with AIDS: 1) the long-term outcomes of ocular Ols; 2) visual impairment among patients without ocular Ols; and 3) host genetic risk factors for and immunologic mechanisms of ocular complications and their outcomes.
描述(申请人提供):艾滋病眼部并发症研究研究组致力于了解和改善艾滋病眼部并发症的结局。艾滋病眼部并发症纵向研究(LSOCA)是在高效抗逆转录病毒治疗(HAART)时代对这些并发症及其结果进行的前瞻性队列研究,目前已进入第九个随访年头。与大多数艾滋病毒感染患者的队列研究从选定的风险组登记不同,LSOCA从所有危险组登记艾滋病患者。截至2006年12月31日,LSOCA队列已经招募了2024名患者,其中448人患有巨细胞病毒性视网膜炎,18人患有其他眼部机会性感染(OLS)。尽管HAART降低了艾滋病患者眼部OLS的发生率,但新病例不断出现,越来越多的艾滋病患者和眼部OLS经历了免疫恢复。虽然已经描述了短期结果,但没有长期数据可用,这些患者对HAART的反应的持久性尚不清楚。长期数据对于评估资源需求和确定管理方针至关重要。在没有眼部OLS的艾滋病患者中,也有视觉系统的异常,表现为对比敏感度降低,通常程度足以影响阅读速度,以及视野丧失。关于这种神经视网膜疾病的发病机制、危险因素和病程,特别是其长期后果,人们知之甚少。此外,在没有眼部OLL的艾滋病患者中,白内障的发病率似乎有所增加,这可能会因HAART的代谢副作用而加剧,如糖尿病和高脂血症。宿主遗传因素对HIV感染过程有实质性影响,但其对眼部并发症的发生率和病程的影响尚不清楚。眼部并发症的免疫学机制也需要更好地阐明。LSOCA队列将解决这些领域对长期数据的持续需求。这项建议的具体目的是评估艾滋病患者中的以下方面:1)眼部OLL的长期结果;2)非眼部OLS患者的视力损害;以及3)眼部并发症及其后果的宿主遗传危险因素和免疫学机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Douglas A Jabs其他文献

GWATCH: a web platform for automated gene association discovery analysis
  • DOI:
    10.1186/2047-217x-3-18
  • 发表时间:
    2014-11-05
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Anton Svitin;Sergey Malov;Nikolay Cherkasov;Paul Geerts;Mikhail Rotkevich;Pavel Dobrynin;Andrey Shevchenko;Li Guan;Jennifer Troyer;Sher Hendrickson;Holli Hutcheson Dilks;Taras K Oleksyk;Sharyne Donfield;Edward Gomperts;Douglas A Jabs;Efe Sezgin;Mark Van Natta;P Richard Harrigan;Zabrina L Brumme;Stephen J O’Brien
  • 通讯作者:
    Stephen J O’Brien

Douglas A Jabs的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Douglas A Jabs', 18)}}的其他基金

ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
阿达木单抗与传统免疫抑制疗法治疗葡萄膜炎(建议)试验
  • 批准号:
    10238823
  • 财政年份:
    2018
  • 资助金额:
    $ 43.34万
  • 项目类别:
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
阿达木单抗与传统免疫抑制疗法治疗葡萄膜炎(建议)试验
  • 批准号:
    10867950
  • 财政年份:
    2018
  • 资助金额:
    $ 43.34万
  • 项目类别:
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
阿达木单抗与传统免疫抑制疗法治疗葡萄膜炎(建议)试验
  • 批准号:
    10480075
  • 财政年份:
    2018
  • 资助金额:
    $ 43.34万
  • 项目类别:
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
阿达木单抗与传统免疫抑制疗法治疗葡萄膜炎(建议)试验
  • 批准号:
    10004650
  • 财政年份:
    2018
  • 资助金额:
    $ 43.34万
  • 项目类别:
Immunologic Determinants of Age-Related Macular Degeneration
年龄相关性黄斑变性的免疫学决定因素
  • 批准号:
    10045618
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:
Developing Classification Criteria for the Uveitides
制定葡萄膜炎的分类标准
  • 批准号:
    9081760
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:
Immunologic determinants of age-related macular degeneration
年龄相关性黄斑变性的免疫学决定因素
  • 批准号:
    9221330
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:
Immunologic Determinants of Age-Related Macular Degeneration (AMD)
年龄相关性黄斑变性 (AMD) 的免疫决定因素
  • 批准号:
    10296003
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:
DEVELOPING CLASSIFICATION CRITERIA FOR THE UVEITIDES
制定 UVEITIDES 的分类标准
  • 批准号:
    10025442
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:
Immunologic Determinants of Age-Related Macular Degeneration (AMD)
年龄相关性黄斑变性 (AMD) 的免疫决定因素
  • 批准号:
    10477332
  • 财政年份:
    2016
  • 资助金额:
    $ 43.34万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.34万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了